428 related articles for article (PubMed ID: 21854869)
1. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
3. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
4. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
An J; Fisher M; Rettig MB
Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
6. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
7. Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy.
Sourbier C; Danilin S; Lindner V; Steger J; Rothhut S; Meyer N; Jacqmin D; Helwig JJ; Lang H; Massfelder T
Cancer Res; 2007 Dec; 67(24):11668-76. PubMed ID: 18089796
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Apoptosis; 2010 Apr; 15(4):412-25. PubMed ID: 19856104
[TBL] [Abstract][Full Text] [Related]
9. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma.
Morais C; Healy H; Johnson DW; Gobe G
Nephrol Dial Transplant; 2010 May; 25(5):1462-74. PubMed ID: 20037166
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
An J; Rettig MB
Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
[TBL] [Abstract][Full Text] [Related]
13. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth.
Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X
Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364
[TBL] [Abstract][Full Text] [Related]
14. Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells.
Malec V; Coulson JM; Urbé S; Clague MJ
J Proteome Res; 2015 Dec; 14(12):5263-72. PubMed ID: 26506913
[TBL] [Abstract][Full Text] [Related]
15. Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway.
Ch'ng WC; Abd-Aziz N; Ong MH; Stanbridge EJ; Shafee N
Cell Oncol (Dordr); 2015 Aug; 38(4):279-88. PubMed ID: 25930675
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.
Wang J; Ma Y; Jiang H; Zhu H; Liu L; Sun B; Pan S; Krissansen GW; Sun X
J Hepatol; 2011 Aug; 55(2):359-68. PubMed ID: 21168458
[TBL] [Abstract][Full Text] [Related]
17. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
[TBL] [Abstract][Full Text] [Related]
18. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
[TBL] [Abstract][Full Text] [Related]
20. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]